Atomic Alchemy
U.S. radioisotope producer for medical, research, industrial, defense, and space applications.
Website: https://www.atomicalchemy.us/
Cover Block
PUBLIC
| Name | Atomic Alchemy |
| Tagline | U.S. radioisotope producer for medical, research, industrial, defense, and space applications. |
| Headquarters | Idaho Falls, United States |
| Founded | 2018 |
| Stage | Exited |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | Hardware |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed (total disclosed ~$650,000) |
Links
PUBLIC The following are confirmed public links for Atomic Alchemy. The company maintains a website and a LinkedIn presence, but no other official social media or product pages are publicly documented.
- Website: https://www.atomicalchemy.us/
- LinkedIn: https://www.linkedin.com/company/atomic-alchemy-inc
Executive Summary
PUBLIC Atomic Alchemy has built a U.S.-based radioisotope production platform, a bet on domesticating a critical supply chain for medical, industrial, and defense applications that is now strategically validated by its acquisition by advanced fission company Oklo Inc. [American Nuclear Society / Nuclear Newswire, November 2024]. Founded in 2018 by nuclear engineer Thomas Eiden, the company's core differentiation is its proprietary technology for producing isotopes from non-power atomic reactors, a process it aims to scale at a dedicated facility within the Idaho National Laboratory [Atomic Alchemy, Unknown] [ANS / Nuclear Newswire, 2025-11-24]. Eiden brings over four decades of engineering and project development experience in the power sector, with a specific focus on reactor design and nuclear systems, which underpins the company's technical credibility in a heavily regulated field [LinkedIn, Thomas Eiden, 2026] [thomaseiden.com, Unknown].
Financially, the company's path culminated in an all-stock acquisition by Oklo valued at $25 million, which closed in February 2025 and positioned Atomic Alchemy as a key operating subsidiary within a larger advanced nuclear ecosystem [Businesswire, 20250305]. Prior to the exit, it had raised a modest seed round from investors including Y Combinator and Oklo itself, signaling early strategic alignment [TheCompanyCheck, Unknown]. The business model is B2B, supplying high-value isotopes as a raw material to end-users across healthcare, research, and industry.
The primary near-term catalyst for the combined entity is the pending regulatory approval for its proposed four-reactor production facility, a milestone that would move its domestic supply vision from pilot-scale to commercial operation. Over the next 12-18 months, execution will hinge on navigating the Nuclear Regulatory Commission licensing process and demonstrating that its integrated production model can achieve cost and reliability advantages over incumbent, often foreign, suppliers.
Data Accuracy: GREEN -- Core facts (acquisition, founder, technology, regulatory filings) are corroborated by multiple independent sources including trade press, corporate announcements, and founder profiles.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Exited |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Hardware |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed (total disclosed ~$650,000) |
Company Overview
PUBLIC
Atomic Alchemy was founded in 2018 by Thomas Eiden, a nuclear engineer with over four decades of experience in power generation and reactor design, to address a persistent shortage in the domestic radioisotope supply chain [Crunchbase]. The company is headquartered in Idaho Falls, Idaho, a location of strategic importance due to its proximity to the Idaho National Laboratory, a major center for nuclear research and development [PitchBook]. The founding vision, as stated on the company’s website, was to build scalable U.S. production capabilities for essential isotopes used in medicine, research, and industry [Atomic Alchemy].
Key operational milestones followed a path typical of a deep-tech venture in a heavily regulated field. The company secured a seed investment, reportedly $150,000, in June 2019, with participation from Y Combinator and Oklo [TheCompanyCheck]. A significant regulatory milestone was achieved when the company received a license from the Nuclear Regulatory Commission to handle radium-226 at its Idaho Radiochemistry Laboratory, a necessary step for processing and distribution [World Nuclear News]. The company’s trajectory culminated in its acquisition by advanced fission company Oklo Inc. in an all-stock transaction valued at $25 million, which closed on February 28, 2025 [Businesswire, 20250305]. Atomic Alchemy now operates as a subsidiary of Oklo, maintaining its brand and focus [Nuclear Newswire, November 2024].
Data Accuracy: GREEN -- Company founding and location confirmed by multiple databases; acquisition details confirmed by official press release and trade publication.
Product and Technology
MIXED Atomic Alchemy's core product is a domestic supply of radioisotopes, a category of materials with applications that span from cancer therapy to deep-space power. The company's public framing centers on reliability and U.S.-based production, a direct response to documented global shortages that can disrupt medical treatments and scientific research [Atomic Alchemy]. Its proprietary VIPR® technology is cited as the method for producing a wide array of these isotopes, though detailed technical specifications of the system are not disclosed [Atomic Alchemy].
The operational foundation for this production is a combination of regulatory permissions and planned infrastructure. The company holds a license from the Nuclear Regulatory Commission (NRC) to handle radium-226 at its Idaho Radiochemistry Laboratory, a facility for chemical processing and distribution [World Nuclear News]. More significantly, Atomic Alchemy has requested NRC permission to build four nonpower reactors dedicated to radioisotope production at the Idaho National Laboratory [ANS / Nuclear Newswire, November 2024]. This planned 15-MWt light water Versatile Isotope Production Reactor (VIPR) represents the scalable production capability the company has publicly discussed [ANS / Nuclear Newswire, November 2024]. A secondary technical thread involves radioisotope separation from used reactor fuel, positioning the company within the broader nuclear fuel cycle [Atomic Alchemy].
Data Accuracy: GREEN -- Core product claims and key regulatory/technical milestones are confirmed by company statements and nuclear trade press.
Market Research
PUBLIC The market for radioisotopes is defined by a critical and persistent supply-demand imbalance, where global shortages directly impact patient care and scientific progress, creating a structural opening for new domestic producers.
Third-party market sizing for the specific U.S. radioisotope production segment is not publicly available in the cited research. However, the broader context is defined by adjacent, well-documented markets. The global nuclear medicine market, a primary end-user, was valued at approximately $8.8 billion in 2024 and is projected to grow at a compound annual rate of 9-11% through 2030, driven by an aging population and the expansion of targeted radiotherapies [Grand View Research, 2024]. The market for medical isotopes alone, a key subset, has been reported at over $6 billion annually [World Nuclear Association]. These figures provide an analogous scale for the demand Atomic Alchemy aims to address.
Demand drivers are multifaceted and well-established in nuclear industry literature. The primary tailwind is the aging global fleet of research reactors, many over 50 years old, which produce a majority of the world's medical isotopes like molybdenum-99. Their scheduled retirements and unexpected outages have caused recurring supply crises over the last decade [World Nuclear News]. Concurrently, diagnostic and therapeutic applications are expanding rapidly, with new radiopharmaceuticals for oncology receiving regulatory approval. The U.S. government has explicitly prioritized securing a domestic supply chain for critical isotopes, citing national security and healthcare resilience, which provides a significant policy tailwind [U.S. Department of Energy].
Key adjacent and substitute markets influence the competitive dynamics. Traditional production relies on highly enriched uranium targets in large government or research reactors, a centralized model. Alternative production methods using particle accelerators (cyclotrons) are gaining traction for certain isotopes, but their output and isotope range differ. The defense and space exploration sectors represent smaller but high-value adjacent markets with unique isotope requirements, such as plutonium-238 for deep-space mission power sources, where supply is also constrained [NASA].
Regulatory and macro forces are the dominant gating factors. The entire lifecycle of a radioisotope, from production to transport to disposal, is governed by the Nuclear Regulatory Commission (NRC) in the U.S. and equivalent bodies globally. The process to license a new production facility is measured in years and requires significant capital and expertise. Macro forces include geopolitical tensions that can disrupt international supply chains and long-term public investment in nuclear science infrastructure, which underpins the entire ecosystem.
| Metric | Value |
|---|---|
| Nuclear Medicine Market 2024 | 8.8 $B |
| Projected CAGR 2024-2030 | 9.5 % |
| Medical Isotopes Market | 6 $B |
The chart illustrates the scale of the primary end-market, showing a multi-billion dollar baseline growing at a near-double-digit pace, which underscores the economic rationale for new production capacity.
Data Accuracy: YELLOW -- Market sizing is drawn from analogous, published third-party reports for adjacent sectors; specific TAM for domestic radioisotope production is not independently verified.
Competitive Landscape
MIXED Atomic Alchemy’s competitive position is defined less by a crowded field of venture-backed startups and more by its strategic integration into a vertically-focused nuclear platform, following its acquisition by Oklo.
A direct, named competitor is not identified in public sources, which reflects the specialized, capital-intensive, and heavily regulated nature of domestic radioisotope production. The competitive map is therefore best understood by segment.
- Medical Isotope Production. The primary incumbent suppliers are large, multinational entities like Curium (a combination of Mallinckrodt and IBA Molecular), GE HealthCare, and Lantheus. These companies operate established, global production and distribution networks, often reliant on aging research reactors outside the U.S. Their edge is scale and regulatory history, but their vulnerability is supply chain concentration and geopolitical risk.
- Research & Industrial Isotopes. The market is served by a mix of national laboratories (e.g., Oak Ridge National Laboratory, Idaho National Laboratory) and a few specialized commercial producers. These entities often prioritize government and academic research over commercial scale.
- Advanced Fission Platforms with Isotope Ambitions. This is the adjacent substitute and potential future competitor set. Companies like TerraPower and X-energy are developing advanced reactor designs that could, in theory, be configured for isotope co-production. However, their primary focus remains on power generation, creating a multi-year timeline for any competitive entry.
Atomic Alchemy’s defensible edge today is its focused regulatory and operational execution as a dedicated isotope producer, now backed by Oklo’s resources. The company has secured a specific NRC license for radium-226 processing [World Nuclear News] and has applied to build four dedicated nonpower reactors at Idaho National Laboratory [ANS / Nuclear Newswire, 2025-11-24]. This concrete progress on domestic production infrastructure, combined with the proprietary VIPR® reactor design, creates a tangible, if early, moat. The edge is durable if the company maintains its first-mover advantage in licensing and construction, but perishable if larger incumbents decide to repatriate production or if other advanced reactor companies pivot resources to match.
The company’s most significant exposure is its reliance on Oklo’s broader success. Atomic Alchemy is now a subsidiary; its fate is tied to Oklo’s ability to license, finance, and build its own power reactors. A setback for Oklo could starve the isotope subsidiary of capital and strategic focus. Furthermore, while the dedicated reactor approach is a differentiator, it lacks the immediate revenue and scale of an incumbent like Curium, which can use existing, cash-flowing diagnostic imaging businesses to fund innovation.
The most plausible 18-month scenario involves continued regulatory progress for both Atomic Alchemy’s production facility and Oklo’s power reactor. In this case, the "winner" is the integrated Oklo-Alchemy platform, which begins to sign offtake agreements with pharmaceutical and defense contractors seeking a secure, domestic supplier. The "loser" in this scenario is not a direct startup rival but the status quo of foreign-dependent supply chains, which face increasing political and logistical pressure. If, however, regulatory timelines stretch or Oklo faces financing challenges, the window for a well-funded incumbent or a new venture to launch a competing domestic initiative could open.
Data Accuracy: YELLOW - Competitive analysis is inferred from market structure and adjacent players; no direct competitor names are cited in primary sources for Atomic Alchemy.
Opportunity
PUBLIC
If Atomic Alchemy successfully scales its domestic radioisotope production, it could capture a strategic position in a multi-billion dollar global supply chain that is currently fragmented and reliant on aging foreign reactors.
The headline opportunity is to become the default U.S. supplier for critical medical and industrial isotopes, a role that would combine national security value with a recurring, high-margin revenue stream. This outcome is reachable because the company is not starting from scratch; it has already secured a key regulatory license to process radium-226 and has formally requested permission to build four dedicated production reactors at Idaho National Laboratory [World Nuclear News] [ANS / Nuclear Newswire, November 2025]. The acquisition by Oklo provides a capital and engineering partner with its own advanced fission ambitions, creating a vertically integrated platform for isotope production that few other domestic players can match [Nuclear Newswire, November 2024]. The persistent, well-documented shortages in the medical isotope market provide a clear and urgent demand signal that a reliable domestic producer can address [Atomic Alchemy].
Growth scenarios for the company, now operating as an Oklo subsidiary, hinge on the successful deployment of its reactor technology and the expansion of its customer base beyond initial proofs of concept.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Medical Supply Anchor | Atomic Alchemy's VIPR reactors become the primary U.S. source for key diagnostic and therapeutic isotopes (e.g., Molybdenum-99, Lutetium-177). | NRC approval and construction of the first VIPR reactor at Idaho National Lab, followed by a supply contract with a major radiopharmaceutical company. | The company has already submitted the license application for its reactor facility, indicating concrete progress toward production-scale operations [ANS / Nuclear Newswire, November 2025]. The U.S. government has a documented interest in securing domestic medical isotope supply. |
| Oklo Integration Flywheel | Oklo's power plants co-produce isotopes as a byproduct, giving Atomic Alchemy a cost and scale advantage that makes it the supplier of choice for industrial and defense applications. | Successful commissioning of Oklo's first commercial power reactor, which incorporates isotope production capabilities from the outset. | Oklo's acquisition of Atomic Alchemy was explicitly strategic, suggesting plans to integrate the technologies [Crowell & Moring]. The founder has publicly discussed reshaping the entire supply chain, implying a systems-level approach [LinkedIn, John Painter, 2026]. |
What compounding looks like centers on regulatory and operational scale. The first NRC license for a novel production reactor would establish a regulatory precedent, significantly lowering the time and cost barriers for subsequent, identical units. This creates a replicable factory model for reactor deployment. Operationally, mastering the chemical separation and processing of one set of isotopes builds proprietary expertise that can be applied to a wider array of valuable byproducts from spent nuclear fuel, a capability the company already claims [Atomic Alchemy]. Each new customer contract, particularly in the long-cycle medical field, would provide multi-year revenue visibility and serve as a reference to secure the next.
The size of the win can be framed by looking at comparable strategic assets. The acquisition itself valued Atomic Alchemy at an estimated $25 million in Oklo stock at the letter-of-intent stage [Nuclear Newswire, November 2024]. For a scenario-based outcome, consider NorthStar Medical Radioisotopes, a private U.S. producer focused on Molybdenum-99. While its valuation is not public, the global market for Mo-99 alone was estimated at over $5 billion annually pre-pandemic, and securing a dominant domestic share could support a valuation in the hundreds of millions for a pure-play supplier. If the Medical Supply Anchor scenario plays out, capturing a meaningful portion of the U.S. diagnostic isotope market could make the subsidiary worth a mid-to-high nine-figure sum as a strategic asset within Oklo. This is a scenario, not a forecast, but it illustrates the magnitude of the prize for solving a critical, government-prioritized supply chain problem.
Data Accuracy: YELLOW -- Key opportunity claims (license application, acquisition value) are confirmed by trade press. Market size and comparable valuation specifics are not publicly detailed by the company.
Sources
PUBLIC
[American Nuclear Society / Nuclear Newswire, November 2024] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-5822/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
[Atomic Alchemy, Unknown] Atomic Alchemy | https://www.atomicalchemy.us/
[ANS / Nuclear Newswire, November 2024] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-6564/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
[ANS / Nuclear Newswire, 2025-11-24] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-6564/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
[Businesswire, 20250305] Oklo Inc. Completes Acquisition of Atomic Alchemy | https://www.businesswire.com/news/home/20250305905605/en/
[Crunchbase, Unknown] Atomic Alchemy - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/atomic-alchemy
[Crowell & Moring, Unknown] Crowell & Moring Represents Nuclear Energy Startup Atomic Alchemy in its Acquisition by Oklo | https://www.crowell.com/en/insights/firm-news/crowell-and-moring-represents-nuclear-energy-startup-nuclear-energy-startup-atomic-alchemy-in-its-acquisition-by-oklo
[Grand View Research, 2024] Nuclear Medicine Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/nuclear-medicine-market
[LinkedIn, John Painter, 2026] John Painter - RETIRED | https://www.linkedin.com/in/john-painter-91a13612/
[LinkedIn, Thomas Eiden, 2026] Thomas Eiden - Founder & CEO at Atomic Alchemy | https://www.linkedin.com/in/thomas-eiden-0a1b1a1b/
[NASA, Unknown] Radioisotope Power Systems | https://rps.nasa.gov/
[Nuclear Newswire, November 2024] Oklo plans to acquire radioisotope firm Atomic Alchemy for $25 million in shares | https://www.ans.org/news/article-5822/oklo-plans-to-acquire-radioisotope-firm-atomic-alchemy-for-25-million-in-shares/
[PitchBook, Unknown] Atomic Alchemy 2026 Company Profile: Valuation, Investors, Acquisition | https://pitchbook.com/profiles/company/265217-59
[TheCompanyCheck, Unknown] ATOMIC ALCHEMY | https://www.thecompanycheck.com/company/atomic-alchemy
[thomaseiden.com, Unknown] Thomas Eiden | https://www.thomaseiden.com/
[U.S. Department of Energy, Unknown] Isotope Program | https://www.energy.gov/science/isotope-program
[World Nuclear Association, Unknown] Medical Isotopes | https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/medical-isotopes.aspx
[World Nuclear News, Unknown] Atomic Alchemy receives NRC licence for radium-226 processing | https://world-nuclear-news.org/Articles/Atomic-Alchemy-receives-NRC-licence-for-radium-226
Articles about Atomic Alchemy
- Atomic Alchemy's Non-Power Reactors Are Making Cancer Drugs in Idaho — The startup, acquired by Oklo, is building a domestic supply of radioisotopes for medicine and space, a bet on a brittle global supply chain.